In a groundbreaking advancement poised to redefine the landscape of gene therapy, scientists have unveiled a revolutionary technique termed “prime assembly” that allows for the precise insertion of remarkably large segments of DNA into the genome. Unlike conventional gene-editing methodologies that typically focus on correcting minute mutations by making small DNA edits, this new approach facilitates the replacement of entire genes, fundamentally expanding therapeutic possibilities for complex genetic disorders.
This innovative technology, detailed in a study published on April 29, 2026, in the journal Nature, builds upon the foundation of prime editing—a precise gene-editing technique combining CRISPR-Cas9 and reverse transcriptase capabilities. The team of researchers, led collaboratively by Bin Liu of The Ohio State University College of Medicine and colleagues from the University of Massachusetts Chan Medical School, devised a method incorporating overlapping DNA flaps that seamlessly integrate donor DNA into the genome without causing the harmful double-strand breaks traditionally associated with large DNA insertions.
Prime assembly deftly circumvents the cytotoxic pitfalls commonly attributed to double-strand breaks in DNA, which can lead to cell death and hinder therapeutic efficacy. By leveraging programmable single-stranded DNA “flaps” generated via twin prime editing strategies, the system fosters a scenario where donor DNA with up to an astonishing 11,000 base pairs can be accurately inserted, representing a quantum leap over the previous limit of approximately 800 base pairs in gene editing. This capacity to transplant vast genetic sequences enables the correction of multiple heterogeneous mutations within a single therapeutic intervention, a feat previously considered unattainable due to regulatory and technical constraints.
The significance of this capability cannot be overstated. Many debilitating genetic diseases are caused by a constellation of mutations scattered throughout a gene or its regulatory regions. Traditional gene therapy approaches would require addressing these mutations individually, complicating development pipelines and requiring multiple approvals. Prime assembly simplifies this by replacing substantial genetic regions wholesale, akin to excising entire paragraphs or chapters from a genome “book” and replacing them with fresh, precise sequences that restore functionality.
Mechanistically, the process involves preparing the donor DNA in the laboratory, which serves as the “healthy” genetic template for insertion. The twin prime editing system creates complementary overlapping flaps on the target DNA locus. These flaps hybridize with ends of the donor DNA, enabling its integration into the genome without the need for error-prone DNA repair pathways like homology-directed repair, which is only efficient in dividing cells. This innovation notably broadens therapeutic applicability to non-dividing cells such as neurons and cardiomyocytes, cell types previously elusive targets for gene therapy.
The team’s in vitro assays in mammalian cells demonstrated not only the impressive efficiency of prime assembly but also its potential safety advantages, as the technique induces only a single-strand DNA break. Such breaks are less detrimental and less likely to trigger apoptosis or other adverse cellular responses compared to double-strand breaks. This attribute positions prime assembly as a powerful candidate for in vivo therapeutic applications where maintaining cellular integrity is paramount.
Further advancing translational potential, the researchers emphasized ongoing work to optimize delivery systems for both the donor DNA and gene editor components. Based on current gene therapy modalities, lipid nanoparticles or adeno-associated viruses (AAVs) are considered the leading vectors to transport these genetic payloads into patients’ cells effectively and safely. The versatility of prime assembly’s design promises compatibility with these delivery vehicles, setting the stage for imminent preclinical and clinical explorations.
Prime assembly inherits its name in homage to Gibson assembly cloning, a widely used molecular biology technique that joins multiple DNA fragments in vitro. Whereas Gibson assembly has revolutionized DNA construction in test tubes, prime assembly translates a similar conceptual framework into a cellular context, effecting large and precise genomic insertions directly inside living cells.
Looking ahead, the research team, including collaborators from Ohio State’s Gene Therapy Institute and experts like ophthalmologist Tom Mendel, plans to rigorously evaluate the efficacy, specificity, and safety of prime assembly in animal models. Such studies will critically inform its readiness for clinical application, potentially transforming treatment paradigms for a host of genetic disorders that have long eluded cure due to their complexity.
Underpinning this scientific leap are extensive collaborative efforts supported by prominent institutions such as the National Institutes of Health, the Leducq Foundation Transatlantic Network of Excellence Program, and the Cystic Fibrosis Foundation. These partnerships reflect the interdisciplinary and high-stakes nature of gene therapy research that melds cutting-edge molecular biology with patient-centered translational goals.
In sum, prime assembly emerges as a beacon of hope in the gene therapy field, promising to unlock large-scale genomic insertions hitherto thought impossible without compromising cell viability. The capacity to insert entire healthy genes tailored to a patient’s unique mutation spectrum could revolutionize treatment options, driving precision medicine deeper into the realm of curative care for heretofore intractable genetic diseases.
The long-term impact of prime assembly technology extends beyond therapeutic applications. It also offers a versatile platform for fundamental research, allowing scientists to study gene function and genomic architecture with unparalleled precision by introducing large, customizable DNA sequences into the genome. This may accelerate discovery across genetics, developmental biology, and regenerative medicine.
As prime assembly continues to mature through successive iterations of experimental validation, its transformative potential will likely catalyze new biotech innovations, spawning a generation of gene therapies that transcend the limitations of existing editing approaches. The future where complex genetic diseases can be robustly treated or cured through large-scale genomic replacement now feels within reach, marking a watershed moment in the annals of biomedical science.
— Written by Emily Caldwell, Emily.Caldwell@osu.edu
Subject of Research: Gene editing technology enabling large genomic insertions via prime assembly
Article Title: Prime assembly with linear DNA donors enables large genomic insertions
News Publication Date: 29-Apr-2026
Web References: https://www.nature.com/articles/s41586-026-10460-4
References: Liu B. et al., “Prime assembly with linear DNA donors enables large genomic insertions,” Nature, April 29, 2026.
Image Credits: Not provided
Keywords
Gene therapy, Prime editing, Large DNA insertion, Genome editing, Twin prime editing, Non-dividing cells, Single-strand break, Homology-directed repair, Lipid nanoparticle delivery, Adeno-associated virus, Genetic disease, Precision medicine
